Assoc. Prof. Atsushi Mizokami, MD, PhD

Department of Integrative Cancer Therapy and Urology at Kanazawa University, Japan

"It is often not possible to use PSA changes to identify worsening or improvements in bone metastatic prostate cancer. BONENAVI - EXINIbone(BSI) - makes it possible to calculate BSI automatically from bone scans. BSI has shown to better correlate with the disease progression of bone metastases and to be more useful in treatment assessment than methods used today.

I also use the BSI values from the BONENAVI reports to discuss disease improvements and changes with our patients. The BSI is easy for them to understand and our patients find it very useful."

Prof. Anders Bjartell, MD, PhD

Department of Urology at Skåne University Hospital, Malmö, Sweden

“For some time now, we have been receiving BSI values from our patients undergoing bone scintigraphy scans. As an imaging biomarker, BSI seems very promising, and preparatory work is now underway to use it in standard clinical practice.

Today, we lack the imaging biomarkers that allow us to easily monitor the results of expensive new drugs in the treatment of metastatic prostate cancer patients. BSI could play an important role in this context.”

Asst. Prof. Andrew Armstrong, MD, ScM

Duke Cancer Institute, Durham, USA

“These results show that BSI can be a valuable and more objective radiologic assessment in trials of men with metastatic castration-resistant prostate cancer, and it is clearly associated with prognosis and disease burden. Tasquinimod had a favorable impact on the BSI over time, confirming our original findings in the randomized phase II trial. The ability to obtain objective measures of bone metastases can help fuel drug development in this disease, where current bone scan assessments are often misclassified and very subjective.”

Caroline Rousseau, MD, PhD

Institut de cancérologie de l'Ouest - René Gauducheau, Nantes, France

In clinical routine, the BSI-calculation in prostate cancer provides an excellent reproducibility.This has been concluded after interpretation by several physicians of the nuclear medicine staff.

Prof. Steven Larson, MD, PhD

Memorial Sloan-Kettering Cancer Center, New York, USA

“BSI obtained at diagnosis is an independent predictor of PCa death.

Adding a BSI to common diagnostic staging parameters (PSA and DRE) greatly enhances prognostic disease information.

Automated BSI scoring, with its 100% ­reproducibility, reduces turnaround time, eliminates operator-dependent subjectivity. We strongly suggest that automated BSI should be included as a parameter in clinical practice.”